Frailty after <scp>COVID</scp>‐19: The wave after?

König, Maximilian; Gollasch, Maik; Komleva, Yulia K.

doi:10.1002/agm2.12258

Cited by 7 publications

(2 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the context of COVID-19, frailty has been shown to independently predict ICU admission and mortality, and to predict disease outcome more accurately than patient age or other comorbidities [56,57]. Patients hospitalized for COVID-19 may demonstrate increased rates of conversion from robust to frail status, and even among patients with noncritical COVID-19 illness, infection has been associated with prolonged fatigue and decreased functional status [58,59 ▪▪ ]. In a recent study of US veterans, frailty was shown to increase the risk of long-term sequelae of COVID-19 illness by over 40% [60 ▪▪ ].…”

Section: Frailty and Decreased Functional Statusmentioning

confidence: 99%

“…In a recent study of US veterans, frailty was shown to increase the risk of long-term sequelae of COVID-19 illness by over 40% [60 ▪▪ ]. Indeed, features of post-COVID syndromes, including a decline in the function of multiple organ systems and decreased physical and mental abilities, overlap significantly with features of frailty syndrome [58].…”

Section: Frailty and Decreased Functional Statusmentioning

confidence: 99%

See 1 more Smart Citation

Lingering effects of COVID-19 in the care of perioperative patients

Jia,

Navare,

Hoyler

2024

Current Opinion in Anaesthesiology

View full text Add to dashboard Cite

Purpose of review Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can lead to organ dysfunction and clinical symptoms beyond the acute infection phase. These effects may have significant implications for the management of perioperative patients. The purpose of this article is to provide a systems-based approach to the subacute and chronic effects of SARS-CoV-2 that are most relevant to anesthesiology practice. Recent findings In 2024, COVID-19 remains a concern for anesthesiologists due ongoing new infections, evolving viral strains, and relatively low rates of booster vaccination in the general population. A growing body of literature describes the post-COVID-19 syndrome in which patients experience symptoms more than 12 weeks after acute infection. Recent literature describes the lingering effects of SARS-CoV-2 infection on all major organ systems, including neurologic, pulmonary, cardiovascular, renal, hematologic, and musculoskeletal, and suggests an increased perioperative mortality risk in some populations. Summary This review offers anesthesiologists an organ system-based approach to patients with a history of COVID-19. Recognizing the long-term sequelae of SARS-CoV-2 infection can help anesthesiologists to better evaluate perioperative risk, anticipate clinical challenges, and thereby optimize patient care.

show abstract

Section: Frailty and Decreased Functional Statusmentioning

confidence: 99%

Section: Frailty and Decreased Functional Statusmentioning

confidence: 99%

Lingering effects of COVID-19 in the care of perioperative patients

Jia,

Navare,

Hoyler

2024

Current Opinion in Anaesthesiology

View full text Add to dashboard Cite

show abstract

Secondary infections and long-term outcomes among hospitalized elderly and non-elderly patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and treated with baricitinib: a comparative study from the national centre of Hungary

Gáspár,

Szabó,

Andrikovics

et al. 2024

GeroScience

View full text Add to dashboard Cite

Baricitinib is considered a first-line treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected adult patients with an associated cytokine storm syndrome (CSS). Our objective was to compare rates of secondary infections and long-term outcomes of elderly and non-elderly patients who received baricitinib for COVID-19. We conducted a single-centre observational study between November 2020 and September 2023, focusing on hospitalized adult SARS-CoV-2 patients with CSS, categorized as elderly (≥ 65 years) and non-elderly (< 65 years). Enrolment, severity stratification, and diagnosis of infectious complications followed predefined criteria. Outcomes of all-cause mortality and rates of non-severe and severe secondary infections were assessed at 1-year post-treatment initiation. Kaplan–Meier analysis was performed for survival analysis. In total, 490 patients were enrolled (median age 65 ± 23 (21–100) years (years, median ± IQR, min–max); 49.18% elderly; 59.59% male). Elderly patients were admitted to the hospital significantly earlier (7 ± 5 days vs. 8 ± 4 days; p = 0.02), experienced a higher occurrence of severe COVID-19 (121/241, 50.21% vs. 98/249, 39.36%; p = 0.02), and required the use of non-invasive ventilation at baseline (167/225, 74.22% vs. 153/236, 64.83%; p = 0.03). At 1 year, all-cause mortality was significantly higher in the elderly subgroup (111/241, 46.06% vs. 29/249, 11.65%; p < 0.01). At 90 days and 1 year, rates of any severe secondary infection were also more prevalent among the elderly (56/241, 23.24% vs. 37/249 14.86%; p = 0.02 and 58/241, 24.07% vs. 39/249, 15.66%; p = 0.02). In conclusion, elderly SARS-CoV-2-infected patients experience a more severe clinical course, higher secondary infection rates, and increased risk for long-term mortality, regardless of immunomodulatory therapy.

show abstract

Association between inflammatory markers, body composition and frailty in home-dwelling elderly: an 8-year follow-up study

Bålsrud,

Ulven,

Ottestad

et al. 2024

GeroScience

View full text Add to dashboard Cite

Frailty has been linked to inflammation and changes in body composition, but the findings are inconsistent. To explore this, we used the Frailty Index (FI) definition to (1) investigate the association between levels of inflammatory markers (baseline) and change in FI score after 8 years of follow-up and (2) investigate the longitudinal associations between inflammatory markers, body composition, and frailty. Home-dwelling elderly (≥ 70 years) were invited to participate in the study and re-invited to a follow-up visit 8 years later. This study includes a total of 133 participants. The inflammatory markers included were high-sensitive C-reactive protein (hs-CRP), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), and glycoprotein acetyls (Gp-acetyls). We used the body composition markers fat mass, fat-free mass, and waist circumference. The FI score consisted of 38 variables. Additional clinical assessments such as blood pressure and body mass index (BMI), as well as information about daily medications, were collected at both visits. Linear regression model and Spearman’s rank correlation were used to investigate associations. We showed that the FI score increased after 8 years, and participants with higher hs-CRP levels at baseline had the largest change in the FI score. Changes in fat mass were significantly correlated with changes in hs-CRP and IL-6, and changes in waist circumference were significantly correlated with changes in TNF-α. The use of drugs increased during the 8 years of follow-up, which may have attenuated the associations between inflammation and frailty. However, elevated concentrations of hs-CRP in the elderly may be associated with an increased risk of frailty in subsequent years.

show abstract

Frailty after COVID‐19: The wave after?

Cited by 7 publications

References 110 publications

Lingering effects of COVID-19 in the care of perioperative patients

Lingering effects of COVID-19 in the care of perioperative patients

Secondary infections and long-term outcomes among hospitalized elderly and non-elderly patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and treated with baricitinib: a comparative study from the national centre of Hungary

Association between inflammatory markers, body composition and frailty in home-dwelling elderly: an 8-year follow-up study

Contact Info

Product

Resources

About